Stock screenerAll disclosures →
EDGAR →
EDIT
Conviction 53HealthcareScan · Thu, Jun 25, 2026EDIT$2.75-1.96%
ResistanceSupportVol 14Insider sell3
Vol MA14 2.35M
Mar 26Apr 14May 1May 19Jun 8Jun 25
WSB mentions · 24h changelatest +0.00%· 3 mentions
Mar 26Apr 14May 1May 19Jun 8Jun 25
Price2.75
Change-1.96%
Gap-0.89%
Rel volume0.44×
Avg volume2.72M
Avg $ vol7.73M
SMA 202.77
SMA 502.92
SMA 2002.67
Price vs 50-5.99%
Price vs 200+2.93%
MA stackmixed
50/200 cross—
Supertrenddown · 3.17
RSI (14)50
MACD hist0.02
MACD crossbull · 2d
Stoch %K / %D61 / 57
ADX (14)14
+DI / −DI25 / 20
RSI divergenceBullish
MACD divergenceBullish
ATR %+9.09%
ADR %8.65%
52w high4.15
52w low1.67
From 52w high-33.86%
Above 52w low+64.86%
New 52w highNo
SqueezeOff
Bollinger width44.60%
%B0.48
Donchian pos32.21%
Donchian high3.58
Donchian low2.35
AVWAP (52w high)2.75
vs AVWAP high-0.31%
AVWAP (52w low)2.73
vs AVWAP low+0.58%
OBV trendFlat
Chaikin MF (20)-0.21
Today vs 20d0.44×
Avg vol (14d)2.35M
Avg vol (20d)2.72M
Avg $ vol (20d)7.73M
Market cap268.75M
RS 3m (vs SPY)+12.19%
RS 6m (vs SPY)+11.92%
RS line new highNo
Trend template4/8
Technical rank49.6
1 week+7.65%
1 month-10.88%
3 months+18.32%
6 months+17.81%
1 year+22.00%
YTD+33.90%
P/E-1.68
P/B60.97
P/S6.63
P/FCF-1.62
EPS-1.80
Div yield—
ROE—
ROA-107.18%
Debt/Eq12.40
Current3.22
EV/EBITDA—
Gross margin—
Net margin-395.01%
Rev growth25.39%
EPS growth32.49%
Price target7.20
Target upside162.30%
Analyst ratingBuy
Institutional40.10%
Ent. value199.78M
Revenue2.83M
Net income-24.98M
Gross profit—
Free cash flow-165.85M
IndustryBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
ExchangeNasdaq
Shares out97.91M
Employees87
ListedWed, Feb 3, 2016
Free float96.07M
Float %98.4%
Short interest15.07M
Days to cover3.4d
Short volume58.6%
Squeeze score61 / 100
Next earnings—
EPS forecast—
Last EPS vs est−$0.26 vs −$0.30
Last surprise+13.3% beat
Setup gradeC
Conviction53 / 100
Pattern quality—
Tech rank49.6 / 100
Group rank50 / 100
Status laneNo active setup
Setup direction—
Pattern family
Resistance3.61
Support2.37
Days since event—
Candle confirm—
News sentiment—
Financials as of Tue, Mar 31, 2026 · quarterly.
Congress activity
Disclosed STOCK Act trades in EDIT
No recent disclosed trades by Congress in EDIT. STOCK Act filings can lag the trade by up to 45 days.
Insider activity
SEC Form 4 transactions in EDIT · 5 buys · 3 sells
| Insider | Side | Shares | Value | Traded | Filed |
|---|---|---|---|---|---|
Connaughton Bernadette Director · Stock Option (right to buy) · 2026-06-17 | Grant | 51.7K | — | 2026-06-17 | 2026-06-22 |
Levy Elliott M. Director · Stock Option (right to buy) · 2026-06-17 | Grant | 51.7K | — | 2026-06-17 | 2026-06-22 |
Scadden David Director · Stock Option (right to buy) · 2026-06-17 | Grant | 51.7K | — | 2026-06-17 | 2026-06-22 |
Hirsch Andrew Director · Stock Option (right to buy) · 2026-06-17 | Grant | 51.7K | — | 2026-06-17 | 2026-06-22 |
Hopfield Jessica Director · Stock Option (right to buy) · 2026-06-17 | Grant | 51.7K | — | 2026-06-17 | 2026-06-22 |
Burkly Linda EVP, CHIEF SCIENTIFIC OFFICER · Common Stock · 2026-06-03 | Sell | 731 | $2K | 2026-06-03 | 2026-06-05 |
O'Neill Gilmore Neil CEO · Common Stock · 2026-06-03 | Sell | 15.38K | $42K | 2026-06-03 | 2026-06-05 |
Parison Amy SVP, Chief Financial Officer · Common Stock · 2026-06-03 | Sell | 464 | $1K | 2026-06-03 | 2026-06-05 |
SEC filings
EDGAR filings in EDIT · 4 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, cancel in one click.
Start free — 7-day full access →Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.